摘要：
Objective:To prepare nanobody-based immunotoxin BI7D12-PE38KDEL targeting EGFR and to examine its cytotoxicity against EGFR positive tumor cells.Methods:By using molecular cloning strategy,prokaryotic expression construct of pET28a-BI7D12-PE38KDEL was generated which consisted of nanobody 7D12 targeting EGFR in the form of a divalent fused with PE38KDEL,a truncated form of pseudomonas exotoxin A via a flexible peptide(G4S)4,and then transformed into E.coli BL21(DE3).Protein expression was induced by adding IPTG,purified by Ni-affinity column chromatography,and verified by Western blot.The binding capacity of the resulted immunotoxin to EGFR-positive cells A549,HT29,MCF-7 and EGFR-negative cells CEM,Jurkat were determined by flow cytometry assay,and its cytotoxicity against the target cells was examined.Briefly,tumor cells were treated with different dosage of the immunotoxin,and the killing efficacy of BI7D12-PE38KDEL on these cells were assessed by WST-1 assay after 72 hours.Results:The SDS-PAGE and Western blot results showed the recombinant immunotoxin BI7D12-PE38KDEL was successfully prepared,and majority of them was expressed in soluble form.BI7D12-PE38KDEL could selectively bind to EGFR-positive cells of A549,HT29,and MCF-7.More importantly,the immunotoxin exhibited much more significant killing effect on these EGFR positive cells compared to the negative control group of CEM and Jurkat cells(P<0.01).Conclusion:In the current study,the nanobody-based immunotoxin BI7D12-PE38KDEL targeting EGFR was successfully prepared and exhibited a superior inhibition effect for the growth of EGFR-positive cells.%目的:构建基于EGFR纳米抗体的免疫毒素BI7D12-PE38KDEL,并检测其对EGFR肿瘤细胞的细胞毒作用.方法:采用分子克隆技术,将靶向EGFR的纳米抗体7D12以二价的形式,通过柔性连接肽(G4S)4与铜绿假单胞菌外毒素的截断形式PE38KDEL连接,构建原核表达载体pET28a-BI7D12-PE38KDEL.然后将其转化到BL21(DE3)感受态细胞,用IPTG进行诱导表达.通过镍柱亲和层析法纯化目的蛋白,并经Western blot验证.通过流式细胞技术检测该免疫毒素与EGFR阳性细胞A549、HT29、MCF-7和EGFR阴性细胞CEM、Jurkat的结合能力后,将其按照一定的浓度梯度进行细胞毒实验研究,72 h后,使用WST-1试剂检测BI7D12-PE38KDEL对上述细胞的杀伤效果.结果:通过SDS-PAGE和Western blot实验验证,成功的制备了重组免疫毒素BI7D12-PE38KDEL,该毒素大部分以可溶性的方式表达.BI7D12-PE38KDEL能够与EGFR阳性的A549、HT29、MCF-7肿瘤细胞特异性的结合,并且对上述细胞的细胞毒作用与阴性对照组CEM和Jurkat相比具有极其显著性差异(P<0.01).结论:成功地构建了基于EGFR纳米抗体的重组免疫毒素BI7D12-PE38KDEL,该免疫毒素能特异性的结合并杀伤EGFR阳性的肿瘤细胞.
